Plasma LOX-Products and Monocyte Signaling Is Reduced by Adjunctive Cyclooxygenase-2 Inhibitor in a Phase I Clinical Trial of Tuberculosis Patients

Plasma LOX-Products and Monocyte Signaling Is Reduced by Adjunctive Cyclooxygenase-2 Inhibitor in a Phase I Clinical Trial of Tuberculosis Patients

IntroductionEicosanoids and intracellular signaling pathways are potential targets for host-directed therapy (HDT) in tuberculosis (TB). We have explored the effect of cyclooxygenase 2 inhibitor (COX-2i) treatment on eicosanoid levels and signaling pathways in monocytes.MethodsPeripheral blood monon...

Full description

Bibliographic Details
Main Authors: Marthe Jøntvedt Jørgensen, Kristin G. Nore, Hans Christian D. Aass, Emilie Layre, Jérôme Nigou, Rasmus Mortensen, Kjetil Tasken, Dag Kvale, Synne Jenum, Kristian Tonby, Anne Ma Dyrhol-Riise
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Cellular and Infection Microbiology
Subjects:
host-directed therapy (HDT)
eicosanoids
cyclooxygenase-2 inhibitor
tuberculosis
monocytes
cytokines
Online Access:https://www.frontiersin.org/articles/10.3389/fcimb.2021.669623/full

Internet

https://www.frontiersin.org/articles/10.3389/fcimb.2021.669623/full

Similar Items